Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive …
To provide insight into the dynamics and source of residual viremia in human
immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 …
immunodeficiency virus (HIV) patients successfully treated with antiretroviral therapy, 14 …
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial
JSG Montaner, P Reiss, D Cooper, S Vella, M Harris… - Jama, 1998 - jamanetwork.com
Context.—Current guidelines recommend that individuals infected with the human
immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents …
immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents …
Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen
C Cohen - HIV clinical trials, 2009 - Taylor & Francis
Virologic failure, or the inability to maintain or achieve viral suppression below detectable
limits (< 50 copies/mL), occurs in some patients with human immunodeficiency virus (HIV)-1 …
limits (< 50 copies/mL), occurs in some patients with human immunodeficiency virus (HIV)-1 …
Predictors of optimal virological response to potent antiretroviral therapy
WG Powderly, MS Saag, S Chapman, G Yu, B Quart… - Aids, 1999 - journals.lww.com
Background: Current potent antiretroviral therapy (using a protease inhibitor and two
nucleoside reverse transcriptase inhibitors) produces a durable suppression of HIV …
nucleoside reverse transcriptase inhibitors) produces a durable suppression of HIV …
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia
S Yerly, L Kaiser, TV Perneger, RW Cone, M Opravil… - Aids, 2000 - journals.lww.com
Objective The current recommendation that patients infected with HIV-1 be treated early is
based on little evidence. We examined whether the early initiation of antiretroviral treatment …
based on little evidence. We examined whether the early initiation of antiretroviral treatment …
Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine
DW Notermans, S Jurriaans, F De Wolf, NA Foudraine… - Aids, 1998 - journals.lww.com
Objectives: Triple combination treatment of HIV-1 infection using two reverse transcriptase
inhibitors and a protease inhibitor can result in significant and sustained decreases in the …
inhibitors and a protease inhibitor can result in significant and sustained decreases in the …
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
F Brun-Vezinet, C Boucher, C Loveday, D Descamps… - The Lancet, 1997 - thelancet.com
Summary Background The Delta trial showed that combination therapy (zidovudine plus
didanosine and zidovudine plus zalcitabine) substantially lengthened life and reduced …
didanosine and zidovudine plus zalcitabine) substantially lengthened life and reduced …
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
L Zhang, B Ramratnam, K Tenner-Racz… - … England Journal of …, 1999 - Mass Medical Soc
Background In patients infected with human immunodeficiency virus type 1 (HIV-1),
combination antiretroviral therapy can result in sustained suppression of plasma levels of …
combination antiretroviral therapy can result in sustained suppression of plasma levels of …
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy
T Doyle, C Smith, P Vitiello, V Cambiano… - Clinical Infectious …, 2012 - academic.oup.com
Abstract (See the Editorial Commentary by Gandhi and Deeks, on pages 733–5.)
Background. Plasma human immunodeficiency virus type 1 (HIV-1) RNA suppression< 50 …
Background. Plasma human immunodeficiency virus type 1 (HIV-1) RNA suppression< 50 …
Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals
Background Relatively little is known about the long-term durability of viral suppression in
individuals initially achieving a viral load of less than 50 copies/ml within 24 weeks of …
individuals initially achieving a viral load of less than 50 copies/ml within 24 weeks of …